Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Virus-like particles |
Clinical data | |
Other names | VBI-2902a |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.[1]